Nexavar (sorafenib tosylate) — United Healthcare

Initial criteria

• Diagnosis of salivary gland tumor AND Disease is recurrent and unresectable OR metastatic

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Nexavar therapy

Approval duration

12 months